References to sources of information used in the production of Living with Hormone Therapy: A guide for men with prostate cancer

How does hormone therapy treat prostate cancer?

Schmitt B, Bennett C, Seidenfeld J et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database of Systematic Reviews 1999, Issue 2.

Who can have hormone therapy?

Augustovski F, Colantonion L, Pichon Riviere A. Androgen deprivation treatment (hormonal therapy) for the management of prostate cancer. Health Technology Assessment 2006, Report ITB No.30.

Kumar S, Shelley M, Harrison C et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006019

National Institute for Health and Clinical Excellence. 2008. Prostate cancer: diagnosis and treatment. Available at http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11924

What types of hormone therapy are there?

Burns-Cox N, Basketter V, Higgins B et al. Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer. International Journal of Urology 2002; 9(8): 431-434.

What does the treatment involve?

Boccon-Gibod L, Hammerer P, Madersbachert S et al. The role of intermittent androgen deprivation therapy in prostate cancer. BJU 2007; 100;738-743.

Loblaw DA, Virgo KS, Nam R et al. Initial hormonal management of androgen-sensitive Metastatic, recurrent, or progressive prostate cancer - 2006 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology 2007; 25(12): 1596-1605.

Schmitt B, Bennett C, Seidenfeld J et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database of Systematic Reviews 1999, Issue 2.

Managing the side effects of hormone therapy 

Loss of sex drive and erectile dysfunction

Mottet, Prayer-Galetti, Hammerert Pet al. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int. 2006; 98: 20-27

Mulhall JP. Saving your Sex Life; a guide for men with prostate cancer.

Potosky AL, Knopf K, Clegg LX et al. Quality-of-Life outcomes after primary androgen deprivation therapy: results from the prostate cancer outcomes study. J Clin Oncol 2009; 19(17):3750-3757.

Sharifi N, Gulley JL, Dahut et al. Androgen deprivation for prostate cancer.JAMA 2005; 294(2):238-244.

Hot flushes

Filshie J, Bolton T, Browne D, Ashley S. Acupuncture and self acupuncture for long-term treatment of vasomotor symptoms in cancer patients--audit and treatment algorithm. Acupunture Medicine 2005; 23(4):171-80.

Gerber, G. S., Zagaja, G. P., Ray, P. S. & Rukstalis, D. B. (2000) Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology, 55: 97-101.

Hammar M, Frisk J, Grimas O et al. Acupuncture treatment of vasomotor symptoms in men with Prostatic carcinoma: a pilot study. J Urol 1999; 161: 853-856.

Harding C, Harris A, Chadwick D. Auricular acupuncture: a novel treatment for vasomotor symptoms associated with luteinizing-hormone releasing hormone agonist treatment for prostate cancer. BJU Int. 2009;103(2):186-90

Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003; 61(Suppl 2A): 32-38.

Mottet, Prayer-Galetti, Hammerert Pet al. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int. 2006; 98: 20-27

Moyad MA. Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology 2002; 59 (Suppl 4A): 20-33.

Bone thinning

Alibhai SMH, Gogov  S, Alllibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Critical reviews in Oncology/Hematology 60 (2006) 201-215

Drudge-Coates L. Bone health: the effect of androgen deprivation therapy in porstate cancer patients. International Journal of Urological Nursing 2007; 1(1): 18-26.

Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007; 177:17-24.

Gomella LG. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU International 2007; 99 Supp.1: 25-29.

Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. The Urologic Clinics of North America 2004; 31:331-352.

Moyad MA. Complimentary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology 2002; 59 (Suppl 4a): 20-33

National Osteoporosis Society. Osteoporosis: causes, prevention and treatment. 2001. Bath: NOS.

Polascik TJ. Bone Health in prostate cancer patients receiving androgen deprivation therapy: the role of bisphosphonates. Prostate Cancer and Prostatic Diseases 2008; 11:3-19.
www.drinkaware.co.uk

Breast swelling and tenderness

Di Lorenzo G, Autorino R, Perdona S et al. Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncology 2005; 6: 972-79.

Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003; 61(Suppl 2A): 32-38.

McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2: 18-27.

Tiredness (fatigue)

Di Lorenzo G, Autorino R, Perdona S et al. Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncology 2005; 6: 972-79.

Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003; 61(Suppl 2A): 32-38.

National Institute for Health and Clinical Excellence. 2008. Prostate cancer: diagnosis and treatment. Available at http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11924

Segal RJ, Reid RD, Courneya KS et al. Resistance training in men receiving androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology 2003; 21: 1653-1659.

Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the androgen deprivation syndrome in men receiving androgen deprivation for prostate cancer. Archives of internal medicine 2006; 166(4): 465-71.

Stone P, Hardy J, Huddart R et al. Fatigue in patients with prostate cancer receiving hormone therapy. European journal of cancer 2000; 36(9): 1134-41.

Strength and muscle loss

Isbarn H, Boccon-Gibod L, Carroll PR et al. Androgen Deprivation for the treatment of prostate cancer: Consider both benefits and risks. Eur Urol. 2008 Oct 14. [Epub ahead of print]

Segal RJ, Reid RD, Courneya KS et al. Resistance training in men receiving androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology 2003; 21: 1653-1659.

Memory and concentration 

Nelson CJ, Lee JS, Gamboa MC et al. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008;113:1097-106.

Risk of heart disease and diabetes

Hakimian P, Blute M, Kashanian J et al. BJU 2008;102:1509-14.

How will hormone therapy affect how I feel?

Beck AM, Robinson JW, Carlson LE et al. Sexual intimacy in heterosexual couples after prostate cancer treatment: What we know and what we still need to learn. Urol Oncol. 2008 Feb 22. [Epub ahead of print]

Helgason AR., Dickman PW, Adolfsson J et al. Emotional Isolation: Prevalence and the Effect on Wellbeing Among 50-80-Year-Old Prostate Cancer Patients, Scand J Urol Nephrol 35: 97-101, 2001

Oliffe J. Embodied masculinity and androgen deprivation therapy. Sociology of Health and Illness 2006; 28(4): 410-432.